(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 October 2022 (13.10.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/217019 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2022/023961

(22) International Filing Date:
08 April 2022 (08.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/172,997 09 April 2021 (09.04.2021) US

(71) Applicant: **CELLDEX THERAPEUTICS, INC.** [US/US]; 53 Frontage Road, Suite 220, Hampton, NJ 08827 (US).

(72) Inventors: **KELER, Tibor**; 53 Frontage Road, Suite 220, Hampton, NJ 08827 (US). **GOLDSTEIN, Joel**; 53 Frontage Road, Suite 220, Hampton, NJ 08827 (US). **MURPHY, Michael, B.**; 53 Frontage Road, Suite 220, Hampton, NJ 08827 (US). **O'NEILL, Thomas**; 2 Foundry Lane, Washington, NJ 07882 (US). **VITALE, Laura, A.**; 53 Frontage Road, Suite 220, Hampton, NJ 08827 (US).

(74) Agent: **REMILLARD, Jane, E.** et al.; Nelson Mullins Riley & Scarborough LLP, One Financial Center, Suite 3500, Boston, MA 02111 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: ANTIBODIES AGAINST ILT4, BISPECIFIC ANTI-ILT4/PD-L1 ANTIBODY AND USES THEREOF

FIG. 10A



(57) Abstract: Provided herein are novel ILT4 antibodies, and antigen binding fragments thereof, as well as bispecific and multispecific constructs binding to ILT4 and PD-L1, comprising such antibodies linked to at least one additional binding agent. Methods of inducing or enhancing an immune response, and methods of treating cancer, by administering the antibodies (or fragments), bispecific constructs, or compositions also are described.

WO 2022/217019 A1